Severe neutropenia is associated with longer overall survival (OS) in patients with pancreatic cancer who receive modified FOLFIRINOX therapy, according to the results of new study.
Pancreatic cancer is the fourth leading cause of cancer-related mortality in the world, mainly due to its late diagnosis. In patients who are diagnosed at the latter stages, chemotherapy is usually the standard of treatment. Read more . . .